ArticleJACC. Case reports2026
Transcatheter Edge-to-Edge Repair Under Argatroban in IABP-Supported Acute Mitral Regurgitation With Suspected Heparin-Induced Thrombocytopenia.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeparin-induced thrombocytopenia (HIT) is a prothrombotic immune-mediated complication that complicates cardiac surgery because cardiopulmonary bypass requires systemic heparinization. We report a case of acute severe mitral regurgitation (MR) complicated by clinically suspected HIT, in which conventional surgical repair was not feasible. CASE SUMMARY: A 59-year-old man presented with acute severe MR due to chordal rupture and developed cardiogenic shock requiring intra-aortic balloon pump support. While awaiting surgery, his platelet count decreased from 262,000/μL to 23,000/μL. The 4Ts score was 6, and PF4/heparin antibody testing was positive, supporting clinically suspected HIT. Because cardiopulmonary bypass requiring systemic heparinization was considered prohibitively high risk, M-TEER was performed under continuous argatroban infusion. Two PASCAL Ace implants were successfully deployed, reducing MR from severe to trivial without thrombotic or bleeding complications. The patient recovered rapidly with immediate IABP removal and early extubation. DISCUSSION: This case demonstrates that M-TEER under argatroban anticoagulation can be a feasible alternative when conventional surgery is precluded by suspected HIT and the anticipated challenges of anticoagulation during cardiopulmonary bypass. TAKE-HOME MESSAGE: M-TEER under argatroban may serve as a rescue strategy for critically ill patients with acute severe MR and suspected HIT when surgical management is not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.